This sharply contrasts with the outcome for CML, for which the prognosis was dramatically improved by the development of imatinib as a specific inhibitor of the BCR-ABL protein and in particular for CML.
•
In 2012 SETBP1 was identified as a novel oncogene in aCML; specific somatic mutations of this gene were discovered in patients affected by atypical Chronic Myeloid Leukemia (aCML) and related diseases.
leukemia | Leukemia & Lymphoma Society | Leukemia | Chronic obstructive pulmonary disease | Acute lymphoblastic leukemia | Promyelocytic leukemia protein | chronic obstructive pulmonary disease | Chronic kidney disease | chronic kidney disease | Chronic fatigue syndrome | Acute myeloid leukemia | Suge Knight Represents: Chronic 2000 | Chronic traumatic encephalopathy | Chronic myelogenous leukemia | Chronic Kidney Disease | chronic fatigue syndrome | Chronic City | T-cell acute lymphoblastic leukemia | Feline leukemia virus | feline leukemia virus | Chronic toxicity | Chronic Town | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | chronic myelogenous leukemia | Chronic mountain sickness | Chronic inflammatory demyelinating polyneuropathy | Chronic bacterial prostatitis | Chronic | Cancer and Leukemia Group B |
In 2012 Dr. Gambacorti-Passerini discovered SETBP1 as a novel oncogene and identified specific mutations of this gene in patients affected by atypical Chronic Myeloid Leukemia (aCML).